New York, May 29, 2026, 04:13 (EDT)
- PPBT was last seen at $2.81 in the U.S., down 16 cents from its last close.
- The company’s $200 million shelf registration is still an overhang for financing and dilution risk.
- Biotech indexes finished higher. Purple Biotech lagged the sector.
Purple Biotech Ltd’s American Depositary Shares ended the U.S. session at $2.81, down 16 cents. The Israeli cancer drug developer is drawing investor scrutiny over cash levels and early-stage pipeline news.
Purple’s cash position is more in focus now than its drug pipeline. The company is still in development, and CAPTN-3, its main program, hasn’t moved past preclinical. So far, there are no human efficacy results for the program.
The stock lagged behind the biotech sector. The SPDR S&P Biotech ETF was up about 1.1% and the iShares Nasdaq Biotechnology ETF gained 1.4% in recent trading. Among oncology-antibody names, Janux Therapeutics rose 2.1%, while MacroGenics dropped 3.8%.
Purple filed a Form F-3 shelf registration with the SEC on May 20 for up to $200 million of securities. The move allows Purple to register securities as it needs to, instead of issuing everything at once. Any offering would require a prospectus supplement, according to the filing. With public float still under $75 million, Purple is capped at primary offerings of about $824,331 in any 12-month period under this registration.
Purple Biotech reported cash, cash equivalents and short-term deposits of $6.4 million at March’s end. Management expects that cash to last through 2027. Net loss for the first quarter came in at $0.1 million. Adjusted net loss was $2.1 million, up from $1.3 million last year.
Purple CEO Gil Efron said the CAPTN-3 platform is the company’s main value driver. “We continue to advance the CAPTN-3 platform as a core value driver,” Efron said Wednesday in the company’s May 15 results statement. CAPTN-3 uses a tri-specific antibody, a lab-made protein targeting three things at once.
Purple says lab tests with patient tumor samples came out in favor of IM1240. The company reported its capped-CD3 × 5T4 × NKG2A tri-specific antibody hit on tumor material that hadn’t responded to earlier therapies. These results support the case in lab settings but aren’t clinical evidence from actual patients treated with the antibody.
Janux is developing tumor-activated T-cell engagers, a type of immuno-oncology therapy that targets immune cells at tumors. MacroGenics describes itself as a clinical-stage biotech focused on antibody cancer drugs.
Bulls face serious risks. Early tumor data may not translate to patients. Small biotech firms such as Purple can run out of cash before reaching larger trials. In a filing with the SEC, Purple flagged fast competition in cancer, IP issues, Israel-related risks, and the chance it could fall short of Nasdaq listing requirements.
PPBT is still trading as a financing story, not as a cancer tech bet. Investors haven’t seen new CAPTN-3 data, a less dilutive raise, or a deal to change that yet. The stock has light trading, cash concerns, and standard biotech risk, with early data still needing to get through trials.
